• Sujata K. Bhatia


Infections with tuberculosis are the seventh leading cause of death worldwide. In 2004, tuberculosis was responsible for 1.5 million deaths or 2.5% of all deaths globally (World Health Organization 2008). The tuberculosis epidemic affects a staggering number of people: at any given time, 13.7 million individuals worldwide suffer from tuberculosis (World Health Organization 2009a). The global incidence of tuberculosis is equally significant, with new infections occurring at an alarming rate. The WHO estimates that 9.27 million new cases of tuberculosis occurred in 2007, compared to 9.24 million new cases in 2006. The disease is predominantly concentrated in developing countries: 55% of global cases occur in Asia and 31% of global cases occur in the African region. In addition, HIV co-infection plays an important role in the epidemiology of tuberculosis. Among the 9.27 million incident cases of tuberculosis that occurred in 2007, approximately 1.37 million (14.8%) were HIV positive. Among the 15 countries with the highest tuberculosis incidence rates, 13 are in Africa, a phenomenon linked to HIV co-infection (World Health Organization 2009a). While tuberculosis can be treated with antimicrobial therapies, the disease has a propensity to recur: on top of the 9.27 million “first episodes” of tuberculosis in 2007, an estimated 1.16 million “subsequent episodes” of tuberculosis occurred in 2007. Such subsequent episodes are defined as episodes occurring in patients who had already experienced at least one previous episode of tuberculosis in the past and who had received at least 1 month of anti-tuberculosis treatment (World Health Organization 2009a). Moreover, tuberculosis pathogens may be either drug susceptible or multidrug resistant; the therapeutic arsenal for both types of pathogens needs improvement. For drug-susceptible tuberculosis, the current four-drug treatment regimen (isoniazid , rifampin , ethambutol , and pyrazinamide ) is effective in most cases, but the treatment takes 6–9 months because the bacteria in the infected host range from rapidly dividing to fully dormant (Webb 2009).


Solid Lipid Nanoparticles PLGA Nanoparticles Extrapulmonary Tuberculosis Miliary Tuberculosis Tuberculous Peritonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Beers MH, Porter RS, Jones TV et al (2006) Merck manual of diagnosis and therapy, 18th edn. Wiley, New York, NYGoogle Scholar
  2. Cox RA (2004) Quantitative relationships for specific growth rates and macromolecular compositions of Mycobacterium tuberculosis, Streptomyces coelicolor A3(2) and Escherichia coli B/r: an integrative theoretical approach. Microbiology 150:1413CrossRefGoogle Scholar
  3. Dye C, Floyd K (2006) Tuberculosis. In: Jamison DT, Breman JG, Measham AR et al (eds) Disease control priorities in developing countries, 2nd edn. IBRD/The World Bank and Oxford University Press, Washington, DCGoogle Scholar
  4. Enarson DA, Rouillon A (1994) The epidemiological basis of tuberculosis control. In: Davis PDO (ed) Clinical tuberculosis. Chapman & Hall, London, UKGoogle Scholar
  5. Frieden TR, Sterling TR, Munsiff SS et al (2003) Tuberculosis. Lancet 362:887CrossRefGoogle Scholar
  6. Gelperina S, Kisich K, Iseman MD et al (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172:1487CrossRefGoogle Scholar
  7. Grosset J (2003) Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 47:833CrossRefGoogle Scholar
  8. Houben ENG, Nguyen L, Pieters J (2006) Interaction of pathogenic mycobacteria within the host immune system. Curr Opin Microbiol 9:76CrossRefGoogle Scholar
  9. Pandey R, Khuller GK (2004) Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother 54:266CrossRefGoogle Scholar
  10. Pandey R, Khuller GK (2005) Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85:227CrossRefGoogle Scholar
  11. Pandey R, Sharma S, Zahoor A et al (2003b) Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52:981CrossRefGoogle Scholar
  12. Pandey R, Zahoor A, Sharma S et al (2003a) Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 83:373CrossRefGoogle Scholar
  13. Peters K, Leitzke S, Diederichs JE et al (2000) Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 45:77CrossRefGoogle Scholar
  14. Rook GAW, Hernandez-Pando R (1996) The pathogenesis of tuberculosis. Annu Rev Microbiol 50:259CrossRefGoogle Scholar
  15. Schluger NW (2005) The pathogenesis of tuberculosis. The first one hundred (and twenty-three) years. Am J Respir Cell Mol Biol 32:251CrossRefGoogle Scholar
  16. Sharma A, Pandey R, Sharma S et al (2004a) Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 24:599CrossRefGoogle Scholar
  17. Sharma A, Sharma S, Khuller GK (2004b) Lectin-functionalized poly(lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 54:761CrossRefGoogle Scholar
  18. Webb S (2009) Public-private partnership tackles TB challenges in parallel. Nat Rev Drug Discov 8:599CrossRefGoogle Scholar
  19. World Health Organization (2008) The global burden of disease: 2004 update. WHO Press, GenevaGoogle Scholar
  20. World Health Organization (2009a) Global tuberculosis control: WHO report 2009. WHO Press, GenevaGoogle Scholar
  21. World Health Organization (2009b) Tuberculosis facts 2009. WHO Press, GenevaGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Central Research and Development, DuPont CompanyWilmingtonUSA

Personalised recommendations